Fosamprenavir contraindications: Difference between revisions

Revision as of 01:45, 4 January 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

LEXIVA is contraindicated:

In patients with previously demonstrated clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome) to any of the components of this product or to amprenavir.

When coadministered with drugs that are highly dependent on cytochrome P450 3A4 (CYP3A4) for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (Table 2).^[1]

Adapted from the FDA Package Insert.

@@ Line 4: / Line 4: @@
+==Contraindications==
+LEXIVA is contraindicated:
+*:In patients with previously demonstrated clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome) to any of the components of this product or to amprenavir.
-<ref>{{Cite web  | last =  | first =  | title = LEXIVA (FOSAMPRENAVIR CALCIUM) TABLET, FILM COATED LEXIVA (FOSAMPRENAVIR CALCIUM) SUSPENSION [VIIV HEALTHCARE COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24feb9be-32a6-45fd-a896-f3e202edd8a9 | publisher =  | date =  | accessdate =  }}</ref>
+*:When coadministered with drugs that are highly dependent on cytochrome P450 3A4 (CYP3A4) for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (Table 2).<ref>{{Cite web  | last =  | first =  | title = LEXIVA (FOSAMPRENAVIR CALCIUM) TABLET, FILM COATED LEXIVA (FOSAMPRENAVIR CALCIUM) SUSPENSION [VIIV HEALTHCARE COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24feb9be-32a6-45fd-a896-f3e202edd8a9 | publisher =  | date =  | accessdate =  }}</ref>
+{|
+|[[File:2.JPG|600px|thumb]]
+|}
 ==References==